Gemini axes CSO and 20% of staff to focus on late-phase plans

Gemini Therapeutics is betting it all on its clinical-phase eye disease prospect. Having built up early-stage activities in gene therapy and other areas, Gemini is now sweeping those programs aside to focus on the lead program.